Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2026)
Quarterly results put Income from Continuing Operations at 55244000.0 for Q1 2026, down 46.07% from a year ago — trailing twelve months through Mar 2026 was 186523000.0 (down 39.08% YoY), and the annual figure for FY2025 was 169099000.0, down 40.22%.
Solid Biosciences has reported Income from Continuing Operations over the past 10 years, most recently at 55244000.0 for Q1 2026.
- Income from Continuing Operations reached 55244000.0 in Q1 2026 per SLDB's latest filing, down from 47356000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 20397000.0 in Q3 2022 and bottomed at 55244000.0 in Q1 2026.
- Median Income from Continuing Operations over the past 5 years was 30352000.0 (2023), compared with a mean of 32111058.82.
- The largest annual shift saw Income from Continuing Operations soared 37.62% in 2023 before it plummeted 84.64% in 2024.
- Over 5 years, Income from Continuing Operations stood at 33032000.0 in 2022, then skyrocketed by 37.62% to 20606000.0 in 2023, then tumbled by 84.64% to 38046000.0 in 2024, then decreased by 24.47% to 47356000.0 in 2025, then dropped by 16.66% to 55244000.0 in 2026.
- Business Quant data shows Income from Continuing Operations for SLDB at 55244000.0 in Q1 2026, 47356000.0 in Q4 2025, and 45136000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -55.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.24 Mn |
| Dec 31, 2025 | -47.36 Mn |
| Sep 30, 2025 | -45.14 Mn |
| Jun 30, 2025 | -38.79 Mn |
| Mar 31, 2025 | -37.82 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -32.94 Mn |
| Jun 30, 2024 | -25.31 Mn |
| Mar 31, 2024 | -24.31 Mn |
| Dec 31, 2023 | -20.61 Mn |
| Sep 30, 2023 | -21.26 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -30.35 Mn |
| Dec 31, 2022 | -33.03 Mn |
| Sep 30, 2022 | -20.40 Mn |
| Jun 30, 2022 | -25.09 Mn |
| Mar 31, 2022 | -25.32 Mn |
| Dec 31, 2021 | -18.65 Mn |
| Sep 30, 2021 | -18.03 Mn |
| Jun 30, 2021 | -18.70 Mn |
| Mar 31, 2021 | -16.90 Mn |
| Dec 31, 2020 | -21.36 Mn |
| Sep 30, 2020 | -21.25 Mn |
| Jun 30, 2020 | -18.99 Mn |
| Mar 31, 2020 | -26.70 Mn |
| Dec 31, 2019 | -32.03 Mn |
| Sep 30, 2019 | -29.31 Mn |
| Jun 30, 2019 | -26.60 Mn |
| Mar 31, 2019 | -29.79 Mn |
| Dec 31, 2018 | -22.00 Mn |
| Sep 30, 2018 | -19.06 Mn |
| Jun 30, 2018 | -18.10 Mn |
| Mar 31, 2018 | -15.91 Mn |
| Dec 31, 2017 | -15.11 Mn |
| Sep 30, 2017 | -13.65 Mn |
| Jun 30, 2017 | -11.84 Mn |
| Mar 31, 2017 | -14.05 Mn |